Medtronic's (NYSE: MDT )
June 6 analyst day was by no means light fare, as the company crammed
quite a bit of information into more than seven hours. While
action-oriented investors are likely disappointed that management's
commentary would seem to suggest a bid for Smith & Nephew (NYSE: SNN )
is not too likely, management laid out a vision of an evolving global
device market where Medtronic is likely to be among the few players with
the scale to really cover all of the major bases. While Medtronic
shares do not appear priced for supreme near-term market outperformance,
they still make sense within a diversified portfolio that tends toward
the conservative.
Continue here:
Is Medtronic a Buy? What Analyst Day Revealed
No comments:
Post a Comment